The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level

Abstract

Get full access to this article

View all access options for this article.

References

Alpert

Thygesen

Antman

. Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959–969.

Teunissen

Khalil

Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552–556.

Kuhle

Malmestrom

Axelsson

. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013; 128: e33–e36.

Lycke

Karlsson

Andersen

. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402–404.

Deisenhammer

Egg

Giovannoni

. EFNS guidelines on disease-specific CSF investigations. Eur J Neurol 2009; 16: 760–770.

Salzer

Svenningsson

Sundstrom

Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16: 287–292.

Gunnarsson

Malmestrom

Axelsson

. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83–89.

Axelsson

Malmestrom

Gunnarsson

. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014; 20: 43–50.

Burman

Zetterberg

Fransson

. Assessing tissue damage in multiple sclerosis: A biomarker approach. Acta Neurol Scand 2014; 130: 81–89.

10.

Gaiottino

Norgren

Dobson

. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PloS One 2013; 8: e75091.

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level – YES

Abstract

Get full access to this article

References